Patents by Inventor Shrikant Deshpande
Shrikant Deshpande has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981734Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.Type: GrantFiled: February 10, 2022Date of Patent: May 14, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
-
Patent number: 11977608Abstract: Traditional food quality monitoring systems fail to monitor the variation of food quality in real-time scenarios. Existing machine learning approaches require dedicated data models for different classes of food items due to differences in characteristics of different food items. Also, to generate such data models, a lot of annotated data is required per food item, which are expensive. The disclosure herein generally relates to monitoring and shelf-life prediction of food items, and, more particularly, to system and method for real-time monitoring and shelf-life prediction of food items. The system generates a data model using a knowledge graph indicative of a hierarchical taxonomy for a plurality of categories of the plurality of food items, which in turn contains metadata representing similarities in physio-chemical degradation pattern of different classes of the food items. This data model serves as a generic data model for real-time shelf-life prediction of different food items.Type: GrantFiled: November 1, 2021Date of Patent: May 7, 2024Assignee: TATA CONSULTANCY SERVICES LIMITEDInventors: Jayita Dutta, Parijat Deshpande, Manasi Samarth Patwardhan, Shirish Subhash Karande, Shankar Kausley, Priya Kedia, Shrikant Arjunrao Kapse, Beena Rai
-
Publication number: 20240095606Abstract: This disclosure relates generally to method and system for predicting shelf life of perishable food items. In supply chain management, current technology provides limited capability in providing relation between visual image of food item and a quality parameter value at different storage conditions. The system includes a quality parameter prediction module and a shelf life prediction module. The method obtains input data from user comprising a visual data and a storage data of each food item. The quality parameter prediction module determines a current quality parameter value of the food item from a look-up table. The shelf life prediction module predicts the shelf life of food item based on the current quality parameter value, a critical quality parameter value and the storage data. The look-up table comprising a plurality of weather zones are generated based on relationship dynamics between the visual image of food item and the quality parameter value.Type: ApplicationFiled: August 22, 2023Publication date: March 21, 2024Applicant: Tata Consultancy Services LimitedInventors: PRIYA KEDIA, SHANKAR KAUSLEY, MANASI SAMARTH PATWARDHAN, SHIRISH SUBHASH KARANDE, BEENA RAI, JAYITA DUTTA, PARIJAT DESHPANDE, ANAND SRIRAMAN, SHRIKANT ARJUNRAO KAPSE
-
Patent number: 11708405Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: December 27, 2019Date of Patent: July 25, 2023Assignee: BRISTOL-MYERS QUIBB COMPANYInventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
-
Publication number: 20220204618Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.Type: ApplicationFiled: February 11, 2022Publication date: June 30, 2022Inventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
-
Publication number: 20220089734Abstract: Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.Type: ApplicationFiled: August 11, 2021Publication date: March 24, 2022Applicants: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Kimberly Ann TIPTON, James William WEST, Shrikant DESHPANDE, John J. ENGLEHARDT
-
Patent number: 11274150Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.Type: GrantFiled: November 14, 2019Date of Patent: March 15, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
-
Patent number: 11117968Abstract: Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.Type: GrantFiled: November 2, 2017Date of Patent: September 14, 2021Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Kimberly Ann Tipton, James William West, Shrikant Deshpande, John J. Englehardt
-
Publication number: 20210155703Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.Type: ApplicationFiled: April 3, 2019Publication date: May 27, 2021Inventors: Li-Sheng Lu, Mark J. Selby, Alan J. Korman, Shrikant Deshpande, Mohan Srinivasan, Jun Zhang, Haichun Huang, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova
-
Publication number: 20200199226Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.Type: ApplicationFiled: November 14, 2019Publication date: June 25, 2020Inventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
-
Publication number: 20200190180Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: December 27, 2019Publication date: June 18, 2020Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
-
Patent number: 10676773Abstract: An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.Type: GrantFiled: March 1, 2016Date of Patent: June 9, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Chetana Rao-Naik, Shrikant Deshpande
-
Patent number: 10556948Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: November 30, 2016Date of Patent: February 11, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
-
Publication number: 20190359714Abstract: Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.Type: ApplicationFiled: November 2, 2017Publication date: November 28, 2019Applicants: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Kimberly Ann TIPTON, James William WEST, Shrikant DESHPANDE, John J. ENGLEHARDT
-
Patent number: 9994633Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: December 22, 2014Date of Patent: June 12, 2018Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
-
Publication number: 20180037921Abstract: An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.Type: ApplicationFiled: March 1, 2016Publication date: February 8, 2018Inventors: Chetana RAO-NAIK, Shrikant DESHPANDE
-
Publication number: 20170158757Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: November 30, 2016Publication date: June 8, 2017Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
-
Publication number: 20150104866Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: December 22, 2014Publication date: April 16, 2015Inventors: Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David B. PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU
-
Patent number: 8945546Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: May 23, 2012Date of Patent: February 3, 2015Assignee: Medarex, L.L.C.Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
-
Publication number: 20120230998Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: May 23, 2012Publication date: September 13, 2012Applicant: MEDAREX, INC.Inventors: Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU